Insider

OKYO

OKYO Pharma Limited

Feb 27 • 04:00PM ET

1.71

-0.01 -0.58 %

Healthcare • Biotechnology • United Kingdom • NASD

Peers: JNJ REGN MRK ABBV BMY NVS PFE AZN-D ROG GSK

Index	-	P/E	-	EPS (ttm)	-0.13	Insider Own	42.43%	Shs Outstand	38.45M	Perf Week	0.59%
Market Cap	69.36M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	0.00%	Shs Float	23.35M	Perf Month	-21.92%
Enterprise Value	65.33M	PEG	-	EPS next Q	-0.05	Inst Own	11.65%	Short Float	2.13%	Perf Quarter	-14.24%
Income	-4.61M	P/S	-	EPS this Y	-54.17%	Inst Trans	-47.51%	Short Ratio	1.80	Perf Half Y	-24.34%
Sales	0.00M	P/B	-	EPS next Y	-31.53%	ROA	-123.47%	Short Interest	0.50M	Perf YTD	-17.39%
Book/sh	-0.09	P/C	16.44	EPS next 5Y	-	ROE	-	52W High	3.35 -48.94%	Perf Year	48.70%
Cash/sh	0.10	P/FCF	-	EPS past 3/5Y	-178.81% -114.91%	ROIC	-	52W Low	1.03 66.02%	Perf 3Y	-28.75%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.85% 10.40%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.21	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.58	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	40.24	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.58	EPS Q/Q	13.41%	SMA20	-8.68%	Beta	-0.02	Target Price	8.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-17.79%	Rel Volume	0.43	Prev Close	1.72
Employees	-	LT Debt/Eq	-	Earnings	Dec 03	SMA200	-24.13%	Avg Volume	276.27K	Price	1.71
IPO	May 17, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	85.71% -	Trades		Volume	119,849	Change	-0.58%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-20-26	Initiated	Piper Sandler	Overweight	$7
Dec-08-25	Initiated	B. Riley Securities	Buy	$5

Feb-23-26 04:15PM	Dow Jones sheds more than 800 points on Trump's latest tariff threat (Proactive)
03:30PM	Nasdaq, Dow Jones start the week lower as Trump resets tariffs (Proactive)
11:56AM	OKYO Pharma to present first-in-human urcosimod data at ARVO 2026 (Proactive)
11:00AM	OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress (GlobeNewswire)
Feb-17-26 04:20PM	Nasdaq posts slim gain in calm trade as Wall Street inches up (Proactive)
03:49PM	Loading…
03:49PM	Nasdaq climbs alongside Dow and S&P 500 in afternoon trading (Proactive)
12:56PM	OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain (Proactive)
Feb-13-26 08:50AM	OKYO Pharma prices $20M offering to fund late-stage eye drug trial (Proactive) -19.35%
Feb-12-26 10:20PM	OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares (GlobeNewswire) +11.28%
04:01PM	OKYO Pharma Announces Public Offering of Ordinary Shares (GlobeNewswire)
Feb-11-26 11:03AM	OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offering (Proactive) -6.70%
10:09AM	OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners (GlobeNewswire)
Feb-10-26 09:36AM	OKYO Pharma appoints Flavio Mantelli as chief medical officer (Proactive) +5.03%
08:00AM	OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer (GlobeNewswire)
Jan-30-26 11:30AM	OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting (GlobeNewswire)
01:18PM	Loading…
Jan-28-26 01:18PM	OKYO Pharma clears key FDA meeting for Urcosimod Phase 2b/3 Trial (Proactive)
07:40AM	OKYO Pharma Announces Successful Type C Meeting with the FDA (GlobeNewswire)
Jan-23-26 07:00AM	FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain (GlobeNewswire) -6.33%
Jan-05-26 07:00AM	OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer (GlobeNewswire) +7.62%
Dec-19-25 07:00AM	OKYO Pharma to Ring the Opening Bell at Nasdaq (GlobeNewswire) +8.56%
Dec-15-25 08:30AM	OKYO Pharma Announces Chairman and Founder Acquires Shares (GlobeNewswire) -8.25%
Dec-11-25 08:30AM	OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain (GlobeNewswire) +6.93%
Dec-03-25 07:00AM	OKYO Pharma Announces Chairman and Founder Acquires Shares (GlobeNewswire) -5.77%
Nov-21-25 08:30AM	OKYO Pharma Announces Chairman and Founder Acquires Shares (GlobeNewswire) +10.99%
Nov-18-25 08:30AM	OKYO Pharma to Present at OIS XV in San Diego (GlobeNewswire)
Oct-29-25 07:00AM	OKYO Pharma to Present at BIO-Europe 2025 in Vienna (GlobeNewswire) +6.67%
Oct-16-25 08:30AM	OKYO Pharma Announces Chairman and Founder Acquires Shares (GlobeNewswire)
Sep-22-25 08:30AM	OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain (GlobeNewswire) +13.64%
Jul-17-25 09:00AM	OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain (GlobeNewswire)
05:47AM	OKYO reports top-line data from neuropathic corneal pain therapy trial (Clinical Trials Arena)
09:21AM	Loading…
Jul-16-25 09:21AM	OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain (GlobeNewswire) +7.64%
Jun-11-25 10:05AM	Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited (ACCESSWIRE) +12.56%
08:30AM	OKYO Pharma to Present at the Bio International Convention (GlobeNewswire)
May-19-25 07:00AM	OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit (GlobeNewswire) +7.91%
May-01-25 07:00AM	FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain (GlobeNewswire)
Apr-30-25 07:00AM	OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain (GlobeNewswire)
Mar-31-25 08:00AM	OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod (GlobeNewswire) -5.93%
Mar-10-25 08:30AM	OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain (GlobeNewswire)
Feb-12-25 07:00AM	OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod (GlobeNewswire)
Jan-31-25 07:00AM	OKYO Pharma Announces Chairman and CEO Acquire Shares (GlobeNewswire)
Jan-30-25 09:45AM	Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited (ACCESSWIRE)
Jan-29-25 08:00AM	OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter (GlobeNewswire)
Jan-23-25 07:11AM	Okyo Pharma receives $1.4M in non-dilutive financing (TipRanks)
Jan-22-25 07:00AM	OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding (GlobeNewswire)
Nov-26-24 07:00AM	OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference (GlobeNewswire)
Nov-15-24 09:00AM	MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Oct-30-24 07:00AM	OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference (GlobeNewswire)
Oct-23-24 07:00AM	OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain (GlobeNewswire) +19.42%
Oct-17-24 07:27AM	OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug (TipRanks)
Oct-16-24 07:00AM	OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain (GlobeNewswire)
Sep-10-24 07:00AM	OKYO Pharma Announces Chairman Acquires Shares (GlobeNewswire) +6.80%
Sep-05-24 07:00AM	OKYO Pharma Announces Chairman Acquires Shares (GlobeNewswire)
Aug-27-24 07:00AM	OKYO Pharma Granted U.S. Patent Covering OK-101's Potential for Treating Symptoms of Dry Eye Disease (GlobeNewswire) +14.72%
Aug-23-24 09:00AM	OKYO Pharma CEO Interview to Air on Bloomberg TV (GlobeNewswire)
09:00AM	OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
07:00AM	OKYO Pharma Announces Chairman Acquires Shares (GlobeNewswire)
Aug-21-24 07:00AM	OKYO Pharma Announces Chairman Acquires Shares (GlobeNewswire)
Aug-15-24 12:13PM	OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-06-24 07:00AM	OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use (GlobeNewswire) +5.26%
Jul-11-24 07:00AM	OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101 (GlobeNewswire) +25.64%
Jul-10-24 07:00AM	OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease (GlobeNewswire)
Jun-26-24 10:29AM	Promising Developments from OKYO Pharma on Dry Eye Disease and Neuropathic Pain Treatment (News Direct)
May-24-24 03:07PM	OKYO Pharma Bullish Thesis (Insider Monkey) -11.06%
May-08-24 07:00AM	OKYO Pharma Announces Participation in May 2024 Investor Conferences (GlobeNewswire)
Apr-30-24 07:00AM	OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO) (GlobeNewswire)
Apr-08-24 07:00PM	OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 (GlobeNewswire)
Apr-02-24 07:00AM	OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery (GlobeNewswire)
Mar-22-24 07:00AM	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 (GlobeNewswire) -12.78%
Mar-21-24 07:00AM	OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial (GlobeNewswire)
Mar-20-24 07:00AM	OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event (GlobeNewswire) +20.00%
Feb-09-24 07:00AM	OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain (GlobeNewswire) +19.58%
Jan-31-24 07:00AM	OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board (GlobeNewswire)
Jan-08-24 07:00AM	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease (GlobeNewswire)
Jan-05-24 09:30AM	OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 (GlobeNewswire) +9.65%
Dec-04-23 07:00AM	OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit (GlobeNewswire)
Oct-31-23 07:00AM	OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction (GlobeNewswire)
Oct-09-23 07:00AM	OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (NCP) (GlobeNewswire) -10.62%
Oct-05-23 07:00AM	OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ('DED') (GlobeNewswire) -9.09%
Sep-15-23 07:00AM	OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares (GlobeNewswire) +12.43%
Sep-14-23 09:15AM	OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares (GlobeNewswire) -10.61%
08:45AM	OKYO Pharma Limited Announces Withdrawal of Public Offering (GlobeNewswire)
Sep-13-23 04:05PM	OKYO Pharma Announces Public Offering of Ordinary Shares (GlobeNewswire)
Sep-08-23 07:00AM	OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (GlobeNewswire)
Aug-30-23 07:00AM	OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (DED) (GlobeNewswire) -17.76%
Aug-29-23 07:00AM	OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule (GlobeNewswire) +8.60%
Aug-15-23 09:00AM	OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023 (GlobeNewswire)
Jul-31-23 02:18AM	OKYO Pharma Limited Announces Withdrawal of Public Offering (GlobeNewswire) -15.00%
Jul-28-23 05:25PM	OKYO Pharma Announces Proposed Public Offering of Ordinary Shares (GlobeNewswire) +17.02%
05:05PM	OKYO Pharma Limited Receives Nasdaq Deficiency Notice (GlobeNewswire)
07:01AM	OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (NCP) Following Announcement of Clinical Trial Agreement with Tufts Medical Center (GlobeNewswire)
Jul-27-23 11:30AM	OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer (GlobeNewswire) +23.28%
Jun-06-23 09:30AM	OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease (GlobeNewswire) -16.57%
May-11-23 07:00AM	OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform (GlobeNewswire) -11.76%
May-09-23 08:45AM	Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited (ACCESSWIRE) -8.92%
May-04-23 01:22PM	OKYO Pharma reaches milestone with first patient screening for dry eye disease trial (News Direct) +6.06%
May-03-23 02:00AM	OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023 (GlobeNewswire) +6.45%
May-02-23 02:00AM	OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease (GlobeNewswire) +9.93%
Apr-25-23 02:00AM	OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease (GlobeNewswire) -6.57%
Apr-18-23 10:00AM	OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay (ACCESSWIRE)

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

OKYO

OKYO Pharma Limited

Upgrade your FINVIZ experience